论文部分内容阅读
继发性甲状旁腺功能亢进是尿毒症的常见并发症,可致骨骼、心血管和神经系统病变,日益受到临床的重视。目前对于继发性甲状旁腺功能亢进的治疗主要有限制磷的摄入、补充活性维生素D制剂以及必要时采取甲状旁腺切除术。动物实验及临床研究显示新型活性维生素D衍生物paricalcitol具有相对选择性的药理作用,能安全有效地抑制甲状旁腺激素的分泌及甲状旁腺的增生而很少引起高钙血症和高磷血症,可替代骨化三醇用于尿毒症特别是长期血液透析病人继发性甲状旁腺功能亢进的治疗。
Secondary hyperparathyroidism is a common complication of uremia, can cause bone, cardiovascular and neurological diseases, increasingly clinically valued. At present, the treatment of secondary hyperparathyroidism is mainly to limit the intake of phosphorus, supplement the active vitamin D preparation and take the parathyroidectomy if necessary. Animal experiments and clinical studies have shown that the new active vitamin D derivative paricalcitol has a relatively selective pharmacological effect, can safely and effectively inhibit parathyroid hormone secretion and hyperplasia of the parathyroid glands rarely cause hypercalcemia and hyperphosphatemia Syndrome, an alternative calcitriol for uremia, especially in patients with long-term hemodialysis secondary hyperparathyroidism treatment.